Clinical Trials
11 trialsNCT06321484 2026-03-04
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT01883297 2024-09-05
"Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University Health Network, Toronto
Phase 1 Active not recruiting
NCT05395052 2023-09-21
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT05895370 2023-06-08
GI-HPVT-01
BGI, China
Phase 1 Unknown
NCT03841110 2023-05-01
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT04630769 2023-04-03
FT516 and IL2 With Enoblituzumab for Ovarian Cancer
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT03970382 2022-08-18
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
PACT Pharma, Inc.
Phase 1 Suspended
NCT05122221 2022-06-28
CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers
Corregene Biotechnology Co., Ltd
Phase 1 Unknown
NCT03213964 2021-03-12
Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT02118285 2017-12-05
Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT02482090 2017-08-16
TIL Therapy for Metastatic Ovarian Cancer
Herlev Hospital
Phase 1 Completed